Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative tislelizumab plus chemoradiotherapy for HER2-negative locally advanced resectable GEJ adenocarcinoma (Phase 2)
ChiCTR2500105244Phase 2Recruiting
- Sponsor
- Liaoning Province Cancer Hospital
- Start
- Jul 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in gastroesophageal junction adenocarcinoma, sponsored by Liaoning Province Cancer Hospital. Primary endpoint: pathological complete response rate. Started Jul 2025; status: recruiting.
02
Drugs
tislelizumab
03
Conditions
gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2500105244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500105244.